PMC:7546716 / 170-460 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":78,"end":86},"obj":"Body_part"},{"id":"T5","span":{"begin":88,"end":99},"obj":"Body_part"},{"id":"T6","span":{"begin":101,"end":103},"obj":"Body_part"},{"id":"T7","span":{"begin":269,"end":271},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":150,"end":158},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":38,"end":39},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":112,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":101,"end":103},"obj":"Chemical"},{"id":"T3","span":{"begin":269,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A2","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A4","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":21,"end":240},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}

{"project":"LitCovid-PubTator","denotations":[{"id":"23","span":{"begin":88,"end":107},"obj":"Gene"},{"id":"24","span":{"begin":269,"end":274},"obj":"Gene"},{"id":"37","span":{"begin":150,"end":158},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Gene:90865"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Gene:90865"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"le future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by dama"}